VK-0214

VK-0214 is an agonist of the thyroid β receptor (TRβ) . By activating the expression of ABCD2, it can reduce the accumulation of very long-chain fatty acids (VLCFAs) and further alleviate glioblastoma multiforme. VK-0214 has the effect of regulating fatty acid metabolism and can be used in the research of X-linked adrenoleukodystrophy (X-ALD) [1].

Product Specifications

CAS Number

[852949-30-5]

UNSPSC

12352005

Target

Thyroid Hormone Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/vk-0214.html

Purity

99.87

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=P(O)(COC1=CC(C)=C(CC2=CC=C(C(CC3=CC=CC=C3)=C2)O)C(C)=C1)O

Molecular Formula

C23H25O5P

Molecular Weight

412.42

References & Citations

[1]McGowan E, et al., Integrative Rare Disease Biomedical Profile based Network Supporting Drug Repurposing, a case study of Glioblastoma. Res Sq [Preprint]. 2023 Apr 18:rs.3.rs-2809689.